Literature DB >> 24373823

Case numbers for a randomized clinical trial of boron neutron capture therapy for Glioblastoma multiforme.

Anja Sander1, Werner Wosniok1, Detlef Gabel2.   

Abstract

Boron neutron capture therapy (BNCT) with Na2B12H11SH (BSH) or p-dihydroxyborylphenylalanine (BPA), and with a combination of both, was compared to radiotherapy with temozolomide, and the number of patients required to show statistically significant differences between the treatments was calculated. Whereas arms using BPA require excessive number of patients in each arm, a two-armed clinical trial with BSH and radiotherapy plus temozolomide is feasible.
© 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  BNCT; BPA; BSH; Design of clinical trials; Glioblastoma

Mesh：

Substances：

Year:  2013        PMID： 24373823     DOI： 10.1016/j.apradiso.2013.11.092

Source DB:  PubMed          Journal:  Appl Radiat Isot        ISSN： 0969-8043            Impact factor:   1.513


  3 in total

Review 1.  The use of radiosensitizing agents in the therapy of glioblastoma multiforme-a comprehensive review.

Authors:  Niklas Benedikt Pepper; Walter Stummer; Hans Theodor Eich
Journal:  Strahlenther Onkol       Date:  2022-05-03       Impact factor: 4.033

2.  Closo-Carboranyl- and Metallacarboranyl [1,2,3]triazolyl-Decorated Lapatinib-Scaffold for Cancer Therapy Combining Tyrosine Kinase Inhibition and Boron Neutron Capture Therapy.

Authors:  Marcos Couto; Catalina Alamón; María Fernanda García; Mariángeles Kovacs; Emiliano Trias; Susana Nievas; Emiliano Pozzi; Paula Curotto; Silvia Thorp; María Alejandra Dagrosa; Francesc Teixidor; Clara Viñas; Hugo Cerecetto
Journal:  Cells       Date:  2020-06-05       Impact factor: 6.600

3.  Cobaltabis(dicarbollide) ([o-COSAN]-) as Multifunctional Chemotherapeutics: A Prospective Application in Boron Neutron Capture Therapy (BNCT) for Glioblastoma.

Authors:  Miquel Nuez-Martinez; Catarina I G Pinto; Joana F Guerreiro; Filipa Mendes; Fernanda Marques; Amanda Muñoz-Juan; Jewel Ann Maria Xavier; Anna Laromaine; Valeria Bitonto; Nicoletta Protti; Simonetta Geninatti Crich; Francesc Teixidor; Clara Viñas
Journal:  Cancers (Basel)       Date:  2021-12-19       Impact factor: 6.639
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.